Announces Interim Results of CLK Inhibitor CTX-712 and MALT-1 Inhibitor CTX-177 at the 2022 ASH Annual Meeting.

Please find below link

Chordia Therapeutics Announces Interim Results from the Phase I Clinical Trial andthe non-clinical study of CLK Inhibitor CTX-712 and the results from thenonclinical study of MALT-1 Inhibitor CTX-177 at the 2022 ASH Annual Meeting.（PDF）